LYEL — Lyell Immunopharma, Inc. Dilution Risk Tracker

Lyell Immunopharma, Inc. (LYEL) has a DilutionScore of 61/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

Cash runway is a key watch item: LYEL has approximately 17 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for LYEL in real-time, scanning EDGAR every 60 seconds. A recent S-3 or registration statement filing appears in LYEL's filing history — this warrants monitoring for subsequent prospectus supplements (Form 424B), which indicate active capital raising. The DilutionWatch screener shows real-time score changes for LYEL alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.